Business Wire

Abionic: International Pivotal Study Successfully Demonstrates Diagnosis of Sepsis within 5 Minutes – 24 Hours Earlier Compared with Current Standard-of-Care

LAUSANNE, Switzerland--(BUSINESS WIRE)--Abionic SA, a developer of disruptive nanotechnology based rapid diagnostic solutions, announced today the successful completion of its multi-center ...
Business Wire

Abionic Receives IVDR Certification for Its Predictive Ultra-Rapid Sepsis Test Allowing the Management of Antibiotic Administration

BSI certification agency has granted Abionic’s abioSCOPE® device and PSP test the IVDR certification for in-vitro diagnostics. This certification complies with Europe’s new In-vitro Diagnostic ...
FierceBiotech

Abionic bags $21M to trial rapid test of sepsis risk

Abionic has raised CHF 20 million ($21 million) to trial a test designed to give physicians rapid insights into patients that are at risk of sepsis. The test builds on Abionic’s work to develop an ...
BioWorld

Abionic’s test enters increasingly competitive sepsis fray

Abionic SA received U.S. FDA 510(k) clearance for its in vitro diagnostic Capsule pancreatic stone protein (PSP) sepsis test. Produced by the pancreas and immune cells, PSP provides an early biomarker ...
Engadget

Five-minute allergy test passes the FDA's scrutiny

A few years ago, researchers from the Swiss Federal Institute of Technology in Lausanne (EPFL) started developing what they eventually dubbed the "world's most rapid" allergy test. Now, that test has ...
Wall Street Journal

Abionic Snares $21 Million for Faster Sepsis Diagnosis

Investors are fueling Abionic SA’s ambition to speed diagnosis of the life-threatening condition sepsis. Sepsis is an extreme response to an infection that can lead to tissue damage, organ failure and ...